NCT02495389View on ClinicalTrials.gov

Mirabegron and Urinary Urgency Incontinence

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 28, 2015

Primary Completion Date

January 29, 2019

Study Completion Date

January 29, 2019

Conditions
Overactive Bladder
Interventions
DRUG

Mirabegron

Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.

Trial Locations (1)

60153

Loyola University Medical Center, Maywood

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Loyola University

OTHER

NCT02495389 - Mirabegron and Urinary Urgency Incontinence | Biotech Hunter | Biotech Hunter